Advertisement

Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema

  • Dan Călugăru
  • Mihai CălugăruEmail author
Letter to the Editor
  • 65 Downloads

Dear Editor:

We would like to address several challenges that have arisen from the study by Campos et al. [1].

There was a selection bias attributable to inclusion in the study of patients with different forms of non-proliferative diabetic retinopathy (mild/moderate/severe) diagnosed with recent diabetic macular edema (DME). It should be noted that 50.8% of the eyes included had a past history of macular photocoagulation (treatment-non-naïve patients). In addition, the treatments administered to patients were different, namely 113 eyes were treated with a loading dose of 0.5 mg ranibizumab (Lucentis; Genentech Inc., South San Francisco, CA, USA), 13 eyes were treated with a loading dose of 2 mg aflibercept (Eylea; Regeneron Pharmaceutical Inc., Tarrytown, NY, USA), and 18 were switched from ranibizumab to aflibercept. Importantly, eyes that developed proliferative diabetic retinopathy and needed panretinal photocoagulation, eyes that were rescued with focal/grid laser, and eyes that...

Notes

Author contribution

Both authors (D.C and M.C) were involved in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review, or approval of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Disclaimer

The authors have full control over the primary data and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.

References

  1. 1.
    Campos A, Campos EJ, do Carmo A, Patricio M, Castro de Sousa JP, Ambrosio AF, Silva RC (2018) Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema. Graefes Arch Clin Exp Ophthalmol.  https://doi.org/10.1007/s00417-018-4072-z Published online: July 23, 2018
  2. 2.
    Călugăru D, Călugăru M (2018) Early response tointravitreal dexamethasone implant therapy in diabetic macular edema may predict visual outcome. Am J Ophthalmol 186:164–165CrossRefGoogle Scholar
  3. 3.
    Călugăru D, Călugăru M (2017) Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National Health Service settting. Am J Ophthalmol 174:175–176CrossRefGoogle Scholar
  4. 4.
    Călugăru D, Călugăru M (2017) Outcomes with as-needed aflibercept and macular laser following the phase lll Vista DME trial: endurance 12-month extension study. Am J Ophthalmol 177:235–236CrossRefGoogle Scholar
  5. 5.
    Călugăru D, Călugăru M (2018) Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment. Am J Ophthalmol 256:1035–1037Google Scholar
  6. 6.
    Călugăru D, Călugăru M (2018) Aflibercept in diabetic macular edema refractory to previous bevacizumab; outcomes and predictors of success. Graefes Arch Clin Exp Ophtalmol 256:1353–1354CrossRefGoogle Scholar
  7. 7.
    Gover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (Spectralis). Am J Ophthalmol 148:266–271CrossRefGoogle Scholar
  8. 8.
    Călugăru D, Călugăru M (2016) Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 168:290–291CrossRefGoogle Scholar
  9. 9.
    Zhang C, Tatham AJ, Medeiros FA, Zangwill LM, Yang Z, Weinreb RN (2014) Assessment of choroidal thickness in healthy and glaucomatous eyes using swept source optical coherence tomography. PLoS One 9(10):e109683CrossRefGoogle Scholar
  10. 10.
    Yiu G, Manjunath V, Chiu SJ, Farsiu S, Mahmoud TH (2014) Effect of anti-vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema. Am J Ophthalmol 158:745–751CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of Medicine Cluj-Napoca/RomaniaCluj-NapocaRomania

Personalised recommendations